Ark Genomic Revolution Etf Current Valuation
| ARKG Etf | USD 23.83 0.61 2.63% |
Valuation analysis of ARK Genomic Revolution helps investors to measure ARK Genomic's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Fairly Valued
Today
Please note that ARK Genomic's price fluctuation is very steady at this time. Calculation of the real value of ARK Genomic Revolution is based on 3 months time horizon. Increasing ARK Genomic's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the ARK etf is determined by what a typical buyer is willing to pay for full or partial control of ARK Genomic Revolution. Since ARK Genomic is currently traded on the exchange, buyers and sellers on that exchange determine the market value of ARK Etf. However, ARK Genomic's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 23.83 | Real 24.1 | Hype 23.85 | Naive 21.85 |
The real value of ARK Etf, also known as its intrinsic value, is the underlying worth of ARK Genomic Revolution ETF, which is reflected in its stock price. It is based on ARK Genomic's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of ARK Genomic's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of ARK Genomic Revolution helps investors to forecast how ARK etf's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of ARK Genomic more accurately as focusing exclusively on ARK Genomic's fundamentals will not take into account other important factors: ARK Genomic Revolution ETF Current Valuation Analysis
ARK Genomic's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, ARK Genomic Revolution has a Current Valuation of 0.0. This indicator is about the same for the ARK ETF Trust average (which is currently at 0.0) family and about the same as Health (which currently averages 0.0) category. This indicator is about the same for all United States etfs average (which is currently at 0.0).
Did you try this?
Run Correlation Analysis Now
Correlation AnalysisReduce portfolio risk simply by holding instruments which are not perfectly correlated |
| All Next | Launch Module |
Fund Asset Allocation for ARK Genomic
The fund invests 99.63% of asset under management in tradable equity instruments, with the rest of investments concentrated in various types of exotic instruments.Asset allocation divides ARK Genomic's investment portfolio among different asset categories to balance risk and reward by investing in a diversified mix of instruments that align with the investor's goals, risk tolerance, and time horizon. Mutual funds, which pool money from multiple investors to buy a diversified portfolio of securities, use asset allocation strategies to manage the risk and return of their portfolios.
Mutual funds allocate their assets by investing in a diversified portfolio of securities, such as stocks, bonds, cryptocurrencies and cash. The specific mix of these securities is determined by the fund's investment objective and strategy. For example, a stock mutual fund may invest primarily in equities, while a bond mutual fund may invest mainly in fixed-income securities. The fund's manager, responsible for making investment decisions, will buy and sell securities in the fund's portfolio as market conditions and the fund's objectives change.
ARK Fundamentals
| Price To Earning | 41.86 X | |||
| Price To Book | 3.26 X | |||
| Price To Sales | 7.63 X | |||
| Number Of Employees | 330 | |||
| Beta | 1.8 | |||
| Total Asset | 2.36 B | |||
| One Year Return | (13.60) % | |||
| Three Year Return | (28.30) % | |||
| Five Year Return | (5.30) % | |||
| Ten Year Return | 2.50 % | |||
| Net Asset | 2.36 B | |||
| Last Dividend Paid | 1.05 | |||
| Equity Positions Weight | 99.63 % |
About ARK Genomic Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ARK Genomic Revolution's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ARK Genomic using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ARK Genomic Revolution based on its fundamental data. In general, a quantitative approach, as applied to this etf, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether ARK Genomic Revolution is a strong investment it is important to analyze ARK Genomic's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact ARK Genomic's future performance. For an informed investment choice regarding ARK Etf, refer to the following important reports:Check out ARK Genomic Piotroski F Score and ARK Genomic Altman Z Score analysis. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
The market value of ARK Genomic Revolution is measured differently than its book value, which is the value of ARK that is recorded on the company's balance sheet. Investors also form their own opinion of ARK Genomic's value that differs from its market value or its book value, called intrinsic value, which is ARK Genomic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ARK Genomic's market value can be influenced by many factors that don't directly affect ARK Genomic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ARK Genomic's value and its price as these two are different measures arrived at by different means. Investors typically determine if ARK Genomic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ARK Genomic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.